在肥胖或超重个体与稳定双极性障碍的利拉格卢提德
Journal of clinical psychopharmacology
|January 16, 2024
概括
在患有双相情感障碍 (BD) 和肥胖或超重的个体中,利拉格卢提德3毫克/天显著降低了体重,并改善了代谢因素. 治疗被发现是安全的,并且在40周内耐受良好.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 精神病学药理疗法精神病学药理疗法
背景情况:
- 肥胖是被诊断患有双相情感障碍 (BD) 的个人中普遍存在的并发症.
- 利拉格卢提德3.0毫克/天是经批准用于慢性体重管理的药物,具有良好的神经精神病学安全性.
研究的目的:
- 评估liraglutide 3 mg/d在促进肥胖或超重个体中减肥的疗效和安全性.
- 评估liraglutide对代谢因子和饮食精神病理学的影响,在这个人群中.
主要方法:
- 一项为期40周的随机,双盲,安慰剂对照试验,涉及60名患有稳定BD的参与者.
- 参与者接受了3毫克/天的利拉格卢提德或安慰剂,以及低热量饮食和增加体力活动.
主要成果:
- 与安慰剂相比,利拉格卢提德治疗导致体重,BMI和血红蛋白A1c水平显著降低.
- 在liraglutide组中,更高比例的参与者实现了≥5%的体重减轻.
- 随着利拉格卢提德的使用,人们观察到过度饮食和饥饿程度的改善.
结论:
- 利拉格卢提德3毫克/天表明,在患有稳定双相情感障碍,肥胖或超重的个体中,体重管理的潜在有效性和安全性.
- 进一步的研究可能会支持利拉格卢提德作为一种治疗选择,用于管理BD中与体重相关的并发症.
相关概念视频
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
Drugs for Treatment of Diarrhea-Predominant IBS
176
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
176
Drugs for Treatment of Constipation-Predominant IBS
170
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
170
Mania and Antimanic Drugs: Overview
184
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
184
Insulin: Dosing Regimen and Adverse Effects
175
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
175
Antidepressant Drugs: MAOIs and Other Agents
237
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
237


